Correction to: Efficacy and safety results from a randomized double-blind study comparing proposed biosimilar ABP 798 with rituximab reference product in subjects with moderate-to-severe rheumatoid arthritis

Gerd Burmester¹ · Edit Drescher² · Pawel Hrycaj³ · David Chien⁴ · Zhiying Pan⁴ · Stanley Cohen⁵

Published online: 23 September 2020

© International League of Associations for Rheumatology (ILAR) 2020

Correction to: Clinical Rheumatology

<https://doi.org/10.1007/s10067-020-05305-y>

This article originally published with the family name and given names of all authors transposed. All author names have now been updated and appear correctly above. The original article has been corrected.

Publisher's note Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

The online version of the original article can be found at <https://doi.org/10.1007/s00431-020-03723-3>

✉ Gerd Burmester
gerd.burmester@charite.de

¹ Department of Rheumatology and Clinical Immunology, Free University and Humboldt University Berlin, Charité University Medicine Berlin, Charitéplatz 1, 10117 Berlin, Germany

² Veszprém Csolnoky Ferenc County Hospital, Veszprém, Hungary

³ Rheumatology, Koscian Municipal Hospital, Koscian, Poland

⁴ Amgen Inc., Thousand Oaks, CA, USA

⁵ Metroplex Clinical Research Center, Dallas, TX, USA